StockData
Neurocrine Biosciences Inc logo

Neurocrine Biosciences Inc (NBIX) stock

NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$165.92+0.61 (+0.37%)

Close on Nov 17, 2026Market cap $16.87BP/E 24.3Yield –

Neurocrine Biosciences pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Neurocrine Biosciences's pe ratio was 25.6× on Nov 11, 2026, against 36.4× a year earlier. Over the last 5 years it ranged from 17.3× to 959.3×, with a median of 42.4×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202625.6×−8.4
2025Dec 31, 202533.9×−2.6
2024Dec 31, 202436.5×−34.3
2023Dec 29, 202370.8×−135.1
2022Dec 30, 2022205.9×+187.3
2021Dec 31, 202118.6×−84.4
2020Dec 31, 2020103.1×−529.2
2019Dec 31, 2019632.3×+488.0
2013Apr 30, 2013144.3×+131.2
2012Oct 31, 201213.1×+0.9
2011Dec 30, 201112.1×–

More Neurocrine Biosciences figures

See a number that looks wrong?